clinical trial · NCT05366010
Oscillation and Lung Expansion (OLE) Therapy for Treatment of Neuromuscular Disease (NMD) Patients
Neuromuscular DiseasesOscillation and Lung Expansion (OLE) therapy
brief summary
The study will be a non-randomized open label pilot study comparing a retrospective control period to an active treatment period with oscillation and lung expansion (OLE) therapy.
started
Nov 4, 2021
primary completion
Feb 27, 2024
completion
Feb 27, 2024
last updated
Jul 31, 2025
detailed description
The study is a decentralized trial. All data will be collected in the patients' homes. The primary objective of the study is to evaluate the impact of OLE to treat respiratory complications of neuromuscular disease patients. The frequency of pulmonary exacerbations and other clinical outcome measures will be assessed to determine the effect of consistent OLE therapy.
official title
Evaluation of Oscillation and Lung Expansion (OLE) Using The Volara® System for Treatment of Respiratory Complications in Patients With Neuromuscular Disease in the Home Setting
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol